The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis

Figure 2

Forest plot of HRs comparing overall survival in patients who received IOCT vs. non-IOCT. Studies are listed on the left with respective number of patients of each treatment, HR with 95% CI, and weight are on the right. HR: hazard ratio; IOCT: immuno-oncology combination treatment; CI: confidence interval.